BR0307557A - Derivados benzenosulfonamida como agentes antipsicóticos - Google Patents

Derivados benzenosulfonamida como agentes antipsicóticos

Info

Publication number
BR0307557A
BR0307557A BR0307557-5A BR0307557A BR0307557A BR 0307557 A BR0307557 A BR 0307557A BR 0307557 A BR0307557 A BR 0307557A BR 0307557 A BR0307557 A BR 0307557A
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
alkoxy
represents hydrogen
integer
Prior art date
Application number
BR0307557-5A
Other languages
English (en)
Inventor
Steven Mark Bromidge
David Gwyn Cooper
Ian Thomson Forbes
Andrew Derrick Gribble
Christopher Nobert Johnson
Andrew P Lightfoot
Stephen Frederick Moss
Andrew H Payne
Shahzad Sharooq Rahman
David R Witty
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203437A external-priority patent/GB0203437D0/en
Priority claimed from GB0203438A external-priority patent/GB0203438D0/en
Priority claimed from GB0204758A external-priority patent/GB0204758D0/en
Priority claimed from GB0204784A external-priority patent/GB0204784D0/en
Priority claimed from GB0212548A external-priority patent/GB0212548D0/en
Priority claimed from GB0219711A external-priority patent/GB0219711D0/en
Priority claimed from GB0224466A external-priority patent/GB0224466D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0307557A publication Critical patent/BR0307557A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS BENZENOSULFONAMIDA COMO AGENTES ANTIPSICóTICOS". A invenção proporciona compostos de fórmula (I) onde A e B representam os grupos - (CH~ 2~)~ m~- e -(CH~ 2~)~ n~-, respectivamente; R^ 1^ representa hidrogênio ou alquila C~ 1-6~; R^ 2^ representa hidrogênio, halogênio, hidroxila, ciano, nitro, hidroxialquila C~ 1-6~, trifluorometila, trifluorometoxila, alquila C~ 1-6~, alcoxila C~ 1-6~, alcoxila C~ 1-6~-alquila C~ 1-6~, cicloalquila C~ 3-7~-alcoxila C~ 1-6~, -(CH~ 2~)~ p~-cicloalquila C~ 3-6~, (CH~ 2~)~ p~-cicloalquiloxila C~ 3-6~, -CO-alquila C~ 1-6~, -SO~ 2~-alquila C~ 1-6~, -SO-alquila C~ 1-6~, -S-alquila C~ 1-6~, alquilsulfoniloxila C~ 1-6~, alquilsulfonila C~ 1-6~-alquila C~ 1-6~, -CO~ 2~-alquila C~ 1-6~, CO~ 2~NR^ 7^R^ 8^, - SO~ 2~NR^ 7^R^ 8^, alquilsulfonamido C~ 1-6~, alquilsulfonamido C~ 1-6~-alquila C~ 1-6~, -(CH~ 2~)~ p~NR^ 7^R^ 8^, alquilamido C~ 1-6~-alquila C~ 1-6~, (CH~ 2~)~ p~NR^ 7^COR^ 8^, arilsulfonila, arilsulfoniloxila, arilsulfonil-alquila C~ 1-6~, arilsulfonilamido, arilcarboxamido, arilsulfonamido-alquila C~ 1-6~, arilcarboxamido-alquila C~ 1-6~, aroíla, aroil-alquila C~ 1-6~, aril-alcanoíla C~1-6~, -SO~ 2~NR^ 7^R^ 8^ arila opcionalmente substituída, heteroarila opcionalmente substituída, ou heterociclila opcionalmente substituída, ou um grupo CONR^ 7^R^ 8^ OU SO~ 2~2NR^ 7^R^ 8^ onde R^ 7^ e R^ 8^ juntamente podem ser fundidos para formar um anel aromático ou não aromático de 5 a 7 membros opcionalmente interrompido por um átomo de O ou de S; R^ 3^ representa hidrogênio ou alquila C~1-6~; Ar representa fenila opcionalmente substituìda ou grupo heteroarila monociclicoopcionalmente substituído; R^ 4^ representa arila opcionalmente substituída ou heteroarila opcionalmente substituída; R^ 7^ e R^ 8^ cada um independentemente representa hidrogênio, alquila C~ 1-6~ ou juntamente formam um anel heterocíclico de 5 a 7 membros; Z representa uma ligação, um átomo de oxigênio ou um alquileno C~ 1-6~; Y representa hidrogênio ou alquila C~ 1-6~; m e n independentemente representam um inteiro selecionado a partir de 1 e 2; p independentemente representa um inteiro selecionado a partir de 0, 1, 2 e 3; q representa um inteiro a partir de 1 a 3; r representa um inteiro a partir de 1 a 4; ou um seu sal farmaceuticamente aceitável ou seu solvato. Os compostos são úteis em terapia, em particular como agentes antipsicóticos.
BR0307557-5A 2002-02-13 2003-02-13 Derivados benzenosulfonamida como agentes antipsicóticos BR0307557A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0203437A GB0203437D0 (en) 2002-02-13 2002-02-13 Novel compounds
GB0203438A GB0203438D0 (en) 2002-02-13 2002-02-13 Compounds
GB0204758A GB0204758D0 (en) 2002-02-28 2002-02-28 Novel compounds
GB0204784A GB0204784D0 (en) 2002-02-28 2002-02-28 Compounds
GB0212548A GB0212548D0 (en) 2002-05-30 2002-05-30 Novel compounds
GB0219711A GB0219711D0 (en) 2002-08-23 2002-08-23 Novel compounds
GB0224466A GB0224466D0 (en) 2002-10-21 2002-10-21 Compounds
PCT/EP2003/001545 WO2003068752A1 (en) 2002-02-13 2003-02-13 Benzenesulfonamide derivatives as antipsychotic agents

Publications (1)

Publication Number Publication Date
BR0307557A true BR0307557A (pt) 2005-01-04

Family

ID=27739513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307557-5A BR0307557A (pt) 2002-02-13 2003-02-13 Derivados benzenosulfonamida como agentes antipsicóticos

Country Status (14)

Country Link
US (1) US20050222124A1 (pt)
EP (1) EP1474399A1 (pt)
JP (1) JP2005526724A (pt)
KR (1) KR20040081201A (pt)
CN (1) CN1630642A (pt)
AU (1) AU2003215558A1 (pt)
BR (1) BR0307557A (pt)
CA (1) CA2475783A1 (pt)
CO (1) CO5611103A2 (pt)
IS (1) IS7388A (pt)
MX (1) MXPA04007920A (pt)
NO (1) NO20043794L (pt)
PL (1) PL371344A1 (pt)
WO (1) WO2003068752A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
ATE323680T1 (de) * 2002-02-13 2006-05-15 Glaxo Group Ltd 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
AR040126A1 (es) 2002-05-29 2005-03-16 Glaxo Group Ltd Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
DE60305519T2 (de) * 2002-10-07 2006-11-23 Glaxo Group Ltd., Greenford Sulfonamidderivate als antipsychotische mittel
GB0321475D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327737D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327738D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compound
GB0327741D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
MXPA06006858A (es) * 2003-12-18 2006-09-04 Abbott Gmbh & Co Kg Tetrahidrobenzacepinas y su uso en la modulacion del receptor d3 de la dopamina.
US20050137186A1 (en) * 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
EP1756094A1 (en) * 2004-06-18 2007-02-28 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
EP2439203B1 (en) * 2004-10-14 2014-11-19 AbbVie Deutschland GmbH & Co KG Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
FR2878524B1 (fr) * 2004-12-01 2007-01-19 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
EP1837332A1 (en) 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
EP2314577A1 (en) * 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
CA3017048C (en) * 2016-03-22 2023-11-07 Helsinn Healthcare Sa Benzenesulfonyl-asymmetric ureas and medical uses thereof
BR112023005344A2 (pt) * 2020-09-23 2023-05-09 St Jude Childrens Res Hospital Inc Análogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin- 5-il)arilsulfonamida substituídos como moduladores da proteína cereblon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CN1087294C (zh) * 1997-07-11 2002-07-10 史密丝克莱恩比彻姆有限公司 新化合物
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
ATE323680T1 (de) * 2002-02-13 2006-05-15 Glaxo Group Ltd 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen

Also Published As

Publication number Publication date
KR20040081201A (ko) 2004-09-20
JP2005526724A (ja) 2005-09-08
PL371344A1 (en) 2005-06-13
WO2003068752A1 (en) 2003-08-21
CN1630642A (zh) 2005-06-22
US20050222124A1 (en) 2005-10-06
NO20043794L (no) 2004-09-10
AU2003215558A1 (en) 2003-09-04
CO5611103A2 (es) 2006-02-28
EP1474399A1 (en) 2004-11-10
MXPA04007920A (es) 2004-11-26
CA2475783A1 (en) 2003-08-21
IS7388A (is) 2004-08-06

Similar Documents

Publication Publication Date Title
BR0307557A (pt) Derivados benzenosulfonamida como agentes antipsicóticos
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
BR0114657A (pt) Compostos de benzamida e seu uso
RU2495873C2 (ru) Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека
AR072900A1 (es) Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
AR047903A1 (es) Compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
WO2002089800A3 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
RU2008128452A (ru) Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
AR047902A1 (es) Compuestos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ATE293101T1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
CO5580778A2 (es) Derivados de lactama como antagonistas para receptores 11cby humanos
PE20091429A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
CY1106947T1 (el) Ανταγωνιστες υποδοχεα θρομβινης
AR054197A1 (es) Medicamentos y metodos combinando un inhibidor de la proteasa hcv y un competidor akr
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
BR9804504A (pt) Isoquinolina-3-carboxamidas substituìdas, sua preparação e seu uso como substâncias farmacêuticas
AR048241A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
AR051215A1 (es) Derivados de quinazolina
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
HRP20050933A2 (en) Organic compounds
HUP0300413A2 (hu) Amidcsoportot viselő benzolgyűrűs csoporttal helyettesített piperidint tartalmazó és rokonszerkezetű vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A. , 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.